Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

01/08/	(12, 04/03/13	
	e of entity SUIT MINERALS LIMITED	
ABN		
27 1	28 806 977	
We (the entity) give ASX the following inform	nation.
	t 1 - All issues nust complete the relevant sections (attach sheets if +Class of +securities issued or to be	
1	issued issued or to be	Fully paid ordinary shares in the Company
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	44,500,000 fully paid ordinary shares (pursuant to Tranche 1 of the placement announced on 3 July).
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

Do the *securities rank equally in all Yes respects from the +issue date with existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, the case of a trust. distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution or interest payment 5 Issue price or consideration \$0.01 per Share 6 Purpose of the issue After paying the expenses of the Offer, the (If issued as consideration for the Company intends to use the funds raised acquisition of assets, clearly identify from the Offer to: those assets) maintain and continue to assess the i. viability of its Vanadium projects in Finland and Sweden: ii. pursue strategic partnerships in relation to the Finland and Sweden vanadium projects; review and assess new resource iii. projects; and general working capital purposes. iv. Is the entity an *eligible entity that has 6a Yes obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i The date the security holder resolution 24 October 2018 6b under rule 7.1A was passed Number of *securities issued without 26,779,100 fully paid ordinary shares 6с security holder approval under rule 7.1

Number of *securities issued with

security holder approval under rule 7.1A

6d

Appendix 3B Page 2 04/03/2013

17,720,900 fully paid ordinary shares

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with	Nil
oe .	security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	MII
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	 i. Issue date 10 July 2019 ii. Issue price \$0.01 per share iii. 15 day VWAP \$0.0125 per share iv. 75% of 15 day VWAP \$0.0094 v. VWAP calculated by Company using data sourced from miraqle.com
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 – NIL securities Listing Rule 7.1A – 131,833 securities
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	10 July 2019

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	⁺ Class
210,018,605 (this number includes the 44,500,000 Tranche 1 shares placed under the placement announced 3 July 2019, noting that after including the maximum 74,342,443 shares to be issued under the Entitlement Offer announced on 3 July 2019, the total number of shares on issued in the Company will be 284,361,048 per the Appendix 3B dated 3 July 2019)	Fully Paid Ordinary shares
56,266,073	Options with an exercise price of \$0.10 per share and an expiry date of 31 October 2021

9 Number and ⁺class of all ⁺securities not quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	⁺ Class
13,008,723	Fully paid ordinary shares escrowed until 23 August 2019.
1,500,000	Options exercisable at \$0.20 on or before 28 February 2020 (escrowed until 23 August 2019),
1,992,000	Options exercisable at \$0.20 on or before 28 February 2021 (escrowed until 23 August 2019),
15,000,000	Options exercisable at \$0.25 on or before 14 August 2021 (escrowed until 23 August 2019),
2,000,000	Options exercisable at \$0.049 each on or before 6 November 2021

Appendix 3B Page 4 04/03/2013

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
850,000	Options exercisable at \$0.25 each on or before 14 August 2021 and which vest on the Company's share price achieving a 30-day VWAP on or before 23 August 2019 (escrowed untl 23 August 2019).
8,000,000	Performance Rights (Class A) convertible into fully paid shares on a 1:1 basis on the terms set out in section 13.4 of the Company's Prospectus dated 19 June 2017 (escrowed until 23 August 2019)
8,000,000	Performance Rights (Class B) convertible into fully paid shares on a 1:1 basis subject to satisfaction of the applicable vesting condition on or before 23 August 2019 and otherwise on the terms set out in section 13.4 of the Company's Prospectus dated 19 June 2017 (escrowed until 23 August 2019).
8,000,000	Performance Rights (Class C) convertible into fully paid shares on a 1:1 basis subject to satisfaction of the applicable vesting condition on or before 23 August 2020 and otherwise on the terms set out in section 13.4 of the Company's Prospectus dated 19 June 2017 (escrowed until 23 August 2019).

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No dividend distribution is envisaged in the near future

Part 2 - Pro rata issue

11	Is security holder approval required?	N/a
12	Is the issue renounceable or non-renounceable?	N/a
13	Ratio in which the *securities will be offered	N/a
14	⁺ Class of ⁺ securities to which the offer relates	N/a
15	⁺ Record date to determine entitlements	N/a
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/a
17	Policy for deciding entitlements in relation to fractions	N/a
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/a
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/a
20	Names of any underwriters	N/a
21	Amount of any underwriting fee or commission	N/a
22	Names of any brokers to the issue	N/a
23	Fee or commission payable to the broker to the issue	N/a

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/a
25	If the issue is contingent on security holders' approval, the date of the meeting	N/a
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/a
28	Date rights trading will begin (if applicable)	N/a
29	Date rights trading will end (if applicable)	N/a
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/a
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/a
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/a
33	⁺ Issue date	N/a
	3 - Quotation of securitied only complete this section if you are applying	
34	Type of ⁺ securities (tick one)	
(a)	*Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, estriction ends, securities issued on expiry or conversion of convertible

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docum	o indicate you are providing the informati ents	ion or
35		securities, the names of the 20 largest holders of the he number and percentage of additional ⁺ securities
36		securities, a distribution schedule of the additional mber of holders in the categories
37	A copy of any trust deed for the	he additional ⁺ securities
Enti	ties that have ticked box 34	·(b)
38	Number of *securities for which *quotation is sought	N/a
39	⁺ Class of ⁺ securities for which quotation is sought	N/a
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they	N/A
	participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

41	Reason for request for quotation now	N/a
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	⁺ Class
N/a	N/a
•	•

Quotation agreement

- ⁺Quotation of our additional ⁺securities are in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Japan pely

Sign here:

Company secretary

Print name: Stephen Kelly

== == == ==

Date: 10 July 2019

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	65,370,468	
Add the following:		
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary 	 (1) 16,100,045 fully paid ordinary shares issued 7 June 2018 (2) 54,054,055 fully paid ordinary shares issued 7 November 2018 (3) 7,297,294 fully paid ordinary shares issued 7 January 2019 (4) 35,705,466 fully paid ordinary shares issued 11 February 2019 N/a 	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	N/a	
"A"	178,527,328	

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	26,779,100
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	26,779,100 fully paid ordinary shares issued 10 July 2019
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	26,779,100
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	26,779,100
Note: number must be same as shown in Step 2	
Subtract "C"	26,779,100
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	NIL
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	178,527,328	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	17,852,733	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	17,720,900 fully paid ordinary shares issued 10 July 2019	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	47.700.000	
"E"	17,720,900	

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	17,852,733
Note: number must be same as shown in Step 2	
Subtract "E"	17,720,900
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	131,833
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.